Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Durable local control of irradiated cancer and distant abscopal effects are presumably immune mediated. To evaluate the role of radiotherapy (RT) for limited progression after anti-CTLA4 checkpoint inhibition, medical records of all patients with surgically incurable stage III or IV melanoma from a single institution who received ipilimumab as first-line immunotherapy and subsequent RT were reviewed. Sixteen patients who received RT to all sites of limited melanoma progression were analyzed. Eight patients with an incomplete initial response to ipilimumab received RT to new or progressive disease, whereas the remaining 8 patients with a complete initial response to ipilimumab received RT to sites of subsequent recurrence. The median interval from ipilimumab initiation to start of RT was 30 weeks (range, 15-130 wk), a timeframe where delayed response to ipilimumab is rare. The RT dose was predominantly 30 Gy in 5 fractions (41%) or 36 Gy in 6 fractions (26%). Brain radiation was limited to stereotactic radiosurgery in a single patient. The median local control with RT was 31.4 months. The median disease control was 18.7 months, defined as the interval from completion of RT to the start of additional systemic therapy known to impact survival (anti-programmed death-1 or targeted BRAF therapy), hospice enrollment, or death. The overall survival at 1 and 2 years was 87% and 61%, respectively. Seven patients (44%) had no evidence of melanoma at median follow-up of 29.5 months since completion of RT with no additional therapy. This series supports use of RT to limited sites of progression following ipilimumab as an alternative to other systemic treatments such as anti-programmed death-1 antibodies.
*Department of Radiation Oncology †Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL.
Lauren M
LM
Kropp
Jennifer F
JF
De Los Santos
Svetlana B
SB
McKee
Robert M
RM
Conry
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000276:immunology*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
Vaccine. 2015 Dec 16;33(51):7415-22
26148880
Cancer Immunol Res. 2016 Apr;4(4):345-53
26873574
Cancer. 2007 Oct 15;110(8):1791-5
17721993
J Exp Med. 2006 May 15;203(5):1259-71
16636135
Front Oncol. 2014 Nov 28;4:325
25506582
Oncoimmunology. 2014 May 14;3:e28780
25083318
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
14967443
JAMA Oncol. 2015 Dec;1(9):1325-32
26270858
Cancer Res. 2011 Apr 1;71(7):2488-96
21300764
Lancet. 2015 Aug 1;386(9992):444-51
26037941
J Clin Oncol. 2015 Jun 10;33(17 ):1889-94
25667295
N Engl J Med. 2010 Aug 19;363(8):711-23
20525992
N Engl J Med. 2011 Jun 30;364(26):2517-26
21639810
J Clin Invest. 2014 Feb;124(2):687-95
24382348
Clin Cancer Res. 2016 Jan 1;22(1):20-5
26362999
J Clin Oncol. 2016 Mar 10;34(8):871-8
26811525
N Engl J Med. 2015 Jun 25;372(26):2521-32
25891173
Lancet Oncol. 2015 Aug;16(8):908-18
26115796
Oncoimmunology. 2015 May 28;4(11):e1046028
26451318
Nature. 2015 Apr 16;520(7547):373-7
25754329
J Immunol. 2012 Jul 15;189(2):558-66
22685313
Blood. 2009 Jul 16;114(3):589-95
19349616
J Exp Med. 2007 Jan 22;204(1):49-55
17210731
Cancer Control. 2008 Jul;15(3):225-32
18596674
N Engl J Med. 2014 Nov 13;371(20):1867-76
25265494
N Engl J Med. 2015 Jul 2;373(1):23-34
26027431
Cancer Immunol Res. 2014 Sep;2(9):831-8
25187273
N Engl J Med. 2012 Mar 8;366(10 ):925-31
22397654
Cancer Cell. 2013 Nov 11;24(5):589-602
24209604
Br J Radiol. 1975 Oct;48(574):863-6
811297